Insider sale reported for CDNA (NASDAQ: CDNA) under 10b5-1 plan
Rhea-AI Filing Summary
Form 144 filing reports proposed sales of Common Stock related to option exercises and vested RSUs. The filing lists 706 shares tied to an exercise of stock options dated 06/04/2026 and 4,129 shares tied to Restricted Stock Units dated 04/15/2025. The filing also records 10,282 shares sold on 04/16/2026 under a 10b5-1 plan for net proceeds of $217,155.84.
Positive
- None.
Negative
- None.
Insights
Routine Form 144 selling disclosure under Section 12 rules.
The filing documents a registered resale activity and option-related issuances: 10,282 shares were sold under a 10b5-1 arrangement on 04/16/2026, with proceeds of $217,155.84. It lists option exercises and vested RSUs as sources of shares.
These records are procedural disclosures required for public resale by insiders; cash‑flow recipients and any transfer restrictions are governed by the underlying agreements and are not detailed here. Subsequent SEC filings may show additional related transactions or clarifications.
Sale proceeds reflect exercise/vesting monetization rather than an open-market discretionary trade.
The entry for 706 shares (exercise of stock options) dated 06/04/2026 and 4,129 RSUs dated 04/15/2025 indicate exercised and vested compensation instruments are the likely source of the shares offered for resale.
Impact on dilution is informational only; the filing does not quantify outstanding share counts tied to these awards. Further filings would be needed to assess total dilution or holder-specific intent.